Cargando…

Neutrophils diminish T-cell immunity to foster gastric cancer progression: the role of GM-CSF/PD-L1/PD-1 signalling pathway

Detalles Bibliográficos
Autores principales:	Zhang, Xu, Xu, Wenrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739856/ https://www.ncbi.nlm.nih.gov/pubmed/28348197 http://dx.doi.org/10.1136/gutjnl-2017-313923

Ejemplares similares

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway
por: Wang, Ting-ting, et al.
Publicado: (2017)

Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity
por: Shi, Yinghong, et al.
Publicado: (2020)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma
por: Rong, Qi-xiang, et al.
Publicado: (2021)

Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis
por: Tang, Di, et al.
Publicado: (2022)

Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
por: Kuang, Dong-Ming, et al.
Publicado: (2009)

Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway
por: Lv, Yipin, et al.
Publicado: (2019)

Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy
por: Shurin, Michael R., et al.
Publicado: (2022)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway
por: Bowers, Nathan L., et al.
Publicado: (2014)

PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine
por: Zhang, Xinji, et al.
Publicado: (2018)

Correction: Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway
Publicado: (2020)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
por: Yajuk, Olga, et al.
Publicado: (2021)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
por: Que, Yi, et al.
Publicado: (2021)

PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
por: Yang, Jiabao, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
por: Wu, Yuanzhong, et al.
Publicado: (2023)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer
por: Yonemitsu, Kimihiro, et al.
Publicado: (2022)

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
por: Moschetta, Michele, et al.
Publicado: (2017)

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors
por: Chen, Li, et al.
Publicado: (2022)

Sepsis in PD-1 light
por: Monneret, Guillaume, et al.
Publicado: (2016)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
por: He, Gaixia, et al.
Publicado: (2015)

T Cell Production of GM-CSF Protects the Host during Experimental Tuberculosis
por: Robinson, Richard T.
Publicado: (2017)

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
por: He, Haihua, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Dual VEGFA/BRAF targeting boosts PD‐1 blockade in melanoma through GM‐CSF‐mediated infiltration of M1 macrophages
por: Comunanza, Valentina, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
por: Kong, Yuehong, et al.
Publicado: (2022)

PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
por: Filippone, A., et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mj5tl954s6s181khedajbhq125